Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pemlimogene merolisbac - Chinook Therapeutics/Jannsen Biotech

Next Previous
Drug Profile

Pemlimogene merolisbac - Chinook Therapeutics/Jannsen Biotech

Alternative Names: ADU 214; JNJ-64041757; JNJ-757

Latest Information Update: 18 Aug 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aduro BioTech
  • Developer Bristol-Myers Squibb; Chinook Therapeutics; Janssen
  • Class Cancer vaccines; Gene therapies; Immunotherapies
  • Mechanism of Action Epidermal growth factor inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 11 Aug 2023 Chinook Therapeutics has been acquired by Novartis
  • 05 Mar 2021 No development reported - Phase-I/II for Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Spain, Belgium, USA (IV)
  • 05 Oct 2020 Aduro Biotech has been merged with Chinook Therapeutics to form Chinook Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top